" class="no-js "lang="en-US"> Versantis - Medtech Alert
Friday, September 12, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Versantis | Pharmtech Focus

Versantis

About Versantis

Versantis
Versantis is a clinical-stage pharmaceutical company developing a new generation of orphan medicines to revolutionize the care of patients with liver and rare pediatric diseases. We address the unmet medical needs in emergency care. Our mission is to support acute decompensations of cirrhosis and to save infants born with rare genetic disorders.

Related Story

Industry News

 GENFIT Acquires Swiss Biotech Versantis for Over CHF105 Million | Pharmtech Focus

GENFIT Acquires Swiss Biotech Versantis for Over CHF105 Million

September 20 2022

GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of […]